Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Journal of Experimental Hematology ; (6): 1493-1497, 2021.
Artículo en Chino | WPRIM | ID: wpr-922284

RESUMEN

OBJECTIVE@#To investigate the relationships between caspase-8 (CASP8), fatty acid synthetase (Fas) gene polymorphisms and prognosis of non-Hodgkin's lymphoma patients in Han nationality.@*METHODS@#The clinical data of 85 patients with non-Hodgkin's lymphoma were analyzed retrospectively. The polymorphisms of CASP8 and Fas gene were detected, and prognosis of the patients were analyzed. The polymorphisms of CASP8 and Fas gene in patients with different prognosis were compared, and the relationships between gene polymorphisms and the poor prognosis of the patients were investigated.@*RESULTS@#The incidence rate of poor prognosis of the patients enrolled in the study was 65.88%. The polymorphisms of CASP8 and Fas genes in the patients with poor or good prognosis were in accordance with Hardy Weinberg's law of genetic balance. The frequencies of GG genotype and G allele at rs 1035142 of CASP8 gene, GA genotype and A allele at rs 1377 of Fas gene in patients with poor prognosis were lower than those of the patients with good prognosis (P<0.05). The frequencies of GT, TT and T alleles at rs 1035142 of CASP8 gene, GG and G alleles at rs 1377 of Fas gene in patients with poor prognosis were higher than those of the patients with good prognosis (P<0.05). The proportions of Ann Arbor stage III-IV and high malignancy in patients with poor prognosis were higher than those of the patients with good prognosis (P<0.05). Logistic multiple regression analysis showed that Ann Arbor stage III-IV, moderate malignant, high malignancy, CASP8 rs 1035142 GT genotype, CASP8 rs 1035142 TT genotype and Fas rs 1377 GG genotype were all the risk factors for the poor prognosis of the patients (P<0.05).@*CONCLUSION@#The poor prognosis rate of non-Hodgkin's lymphoma patients in Han nationality is relatively high, and the risk factors for the prognosis of the patients include Ann Arbor stage III-IV, moderate and high malignancy, CASP8 rs 1035142 GT genotype, CASP8 rs 1035142 TT genotype and Fas rs 1377 GG genotype.


Asunto(s)
Humanos , Caspasa 8/genética , Etnicidad , Ácidos Grasos , Ligasas , Linfoma no Hodgkin/genética , Polimorfismo Genético , Pronóstico , Estudios Retrospectivos , Receptor fas
2.
Journal of Experimental Hematology ; (6): 1939-1945, 2020.
Artículo en Chino | WPRIM | ID: wpr-879996

RESUMEN

OBJECTIVE@#To investigate the effect of lncRNA-CASC2 (CASC2) /miR-155-5p/APC axis to the progression of non-Hodgikn lymphoma (NHL).@*METHODS@#The expression level of CASC2 and miR-155-5p in NHL cell lines were examined by qRT-PCR. Dual-luciferase reporter gene assay was used to verify the relationship between miR-155-5p, CASC2 and APC. The effects of CASC/miR-155-5p/APC axis to the proliferation, invasion and apoptosis of NK-92 cells were detected by MTT, Transwell assay and flow cytometry assay, respectively.@*RESULTS@#CASC2 was downregulated in NHL cell lines. Overexpression of CASC2 could inhibit the proliferation and invasion of NK-92 cells, and promote its apoptosis. Dual-luciferase reporter gene assay confirmed that there was a targeting relationship between miR-155-5p, CASC2 and APC. The restoration experiments proved that knockdown of both miR-155-5p and CASC2 or APC could restore the inhibitory effect of miR-155-5p silencing to the biological behavior of NK-92 cells.@*CONCLUSION@#Overexpression of CASC2 suppresses the proliferation and invasion of NK-92 cells, promote the apoptosis of NK-92 cells via targeting miR-155-5p and upregulating APC expression.


Asunto(s)
Humanos , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica , Linfoma no Hodgkin/genética , MicroARNs/genética , ARN Largo no Codificante/genética , Proteínas Supresoras de Tumor/genética
3.
Journal of Huazhong University of Science and Technology (Medical Sciences) ; (6): 185-7, 2006.
Artículo en Inglés | WPRIM | ID: wpr-634342

RESUMEN

To investigate p120 catenin mRNA expression in Non-Hodgkin's lymphoma (NHL) cell lines (U937, Raji, Jurkat and Molt4) and normal lymphocytes and explore the relationship between p120 catenin and Non-Hodgkins lymphoma, total RNA sample was extracted by using TRIzol and reversely transcripted into cDNA. Polymerase chain reaction was performed to detect mRNA expression of p120 catenin in NHL cell lines U937, Raji, Jurkat and Molt4. Normal lymphocytes were used as control. It was found expressions of p120 catenin 1A and 3A mRNA were high in above-mentioned NHL cell lines, but neither p120 catenin 1A nor 3A was found in normal lymphocytes as shown by RT-PCR. It is concluded that both P120ctn1A and P120ctn3A mRNA transcripts were found in all NHL cell lines U937, Raji, Jurkat and Molt4 but they don't exist in normal lymphocytes, suggesting p120ctn possibly is of importance in diagnosis and therapy of lymphoma.


Asunto(s)
Cateninas/genética , Moléculas de Adhesión Celular/genética , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica , Células Jurkat , Linfoma no Hodgkin/genética , Linfoma no Hodgkin/patología , Fosfoproteínas/genética , ARN Mensajero/genética , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Biomarcadores de Tumor/genética , Células U937
4.
Journal of Korean Medical Science ; : 645-651, 2006.
Artículo en Inglés | WPRIM | ID: wpr-191667

RESUMEN

The metastasis-suppressing role of the nm23 gene in the metastatic spread of malignant tumor is still debated. We examined the nm23-H1 protein expression and gene mutation in non-Hodgkin's lymphomas to compare with the clinicopathologic parameters. The expression of nm23-H1 protein was immunohistochemically examined in 150 cases of non-Hodgkin's lymphomas; 85 diffuse large B cell lymphomas (DL-BCL), 18 marginal zone B cell lymphomas (MZL), 3 mantle cell lymphomas, 25 peripheral T cell lymphomas, not otherwise specified (TCLNOS), and 19 NK/T cell lymphomas (NK/T). Eighty-one cases (58 DLBCL, 6 MZL, 4 TCLNOS, and 13 NK/T) were studied for nm23-H1 gene mutation in exon 1 to 5. The high expression of nm23-H1 protein was associated with the high IPI score (p=0.019) and the low survival rate of the patients (p=0.0039). The gene mutation of nm23-H1 was detected in 10.3% of DLBCL and 30.7% of NK/T; but none in MZL and TCLNOS. The mutation was found in exon 1 in 5 cases, exon 2 in two cases, exon 4 in one case and both exon 1 and 2 in two cases. Our results suggest that the expression of nm23-H1 protein can be used as a poor prognostic marker in non-Hodgkin's lymphomas, and the mutational change of gene may operate in the lymphomagenesis.


Asunto(s)
Persona de Mediana Edad , Masculino , Humanos , Femenino , Análisis de Matrices Tisulares , Análisis de Supervivencia , Pronóstico , Polimorfismo Conformacional Retorcido-Simple , Nucleósido-Difosfato Quinasa/genética , Mutación/genética , Linfoma de Células T/genética , Linfoma no Hodgkin/genética , Linfoma de Células del Manto/genética , Linfoma de Células B Grandes Difuso/genética , Linfoma de Células B/genética , Inmunohistoquímica , Análisis Mutacional de ADN , Secuencia de Bases
5.
Rev. bras. cancerol ; 47(3): 291-301, jul.-set. 2001. ilus
Artículo en Portugués | LILACS | ID: lil-359098

RESUMEN

Os linfomas não Hodgkin de origem B na infância são neoplasias de alto grau de malignidade, predominando os linfomas do tipo Burkitt e não Burkitt. O linfoma de Burkitt apresenta dois subtipos, o endêmico e o esporádico, ambos caracterizados por translocações cromossômicas envolvendo o proto-oncogene c-myc que resultam na perda de regulação desse gene. Embora a função normal do c-myc permaneça enigmática, recentes dados indicam que esse gene desempenha um papel importante em diversos aspectos da biologia celular, incluindo proliferação, diferenciação, metabolismo e apoptose. Nesta revisão são abordados os aspectos epidemiológicos, clínicos e moleculares dos linfomas B da infância e o papel da ativação do gene c-myc associado a mutações dos genes p53 e Rb na patogênese dos linfomas de Burkitt. O papel da infecção pelo vírus Epstein-Barr (EBV), sua relevância na indução da carcinogenese e interação das proteínas virais com proteínas dos genes supressores de tumor é também discutido.


Asunto(s)
Humanos , Masculino , Femenino , Preescolar , Niño , Linfoma de Burkitt , Linfoma no Hodgkin/genética , Linfoma de Células B/genética , Linfoma de Células B/patología , Biología Molecular
6.
Journal of Korean Medical Science ; : 59-64, 2000.
Artículo en Inglés | WPRIM | ID: wpr-43383

RESUMEN

To determine whether the p53 expression might be a predictor for treatment sponse and overall survival in nodal non-Hodgkin's lymphoma (NHL), we analyzed e expression of p53 in 69 NHL patients. p53 protein expression was analyzed by munohistochemistry with long-term follow up (1-148 months: median 12.2). p53 pression was noted in 23/69 (33.3%) patients. Complete response (CR) rate to stemic chemotherapy was correlated with stage (I/II) (p=0.038), but not with 3 expression (p=0.2856). Poor overall survival was associated with stage =0.0010) or IPI score (p=0.0076), but not with p53 expression (p=0.8601). From ratification analysis by stage, in stage III/IV patients, the p53 positive oup had a trend to be associated with poor overall survival than the p53 gative group. Multivariate analysis revealed that p53 positive group was sociated with less CR rate compared to the p53 negative group (p=0.046), ereas overall survival was correlated with stage (p=0.0320), not with p53 atus. p53 expression was associated with less CR rate in patients with DLBL. rther studies with large numbers of samples and homogenous group of NHL are eded to determine the prognostic value of cell cycle regulator, p53 in NHL.


Asunto(s)
Femenino , Humanos , Masculino , Anticuerpos Monoclonales , Proteínas de Ciclo Celular/biosíntesis , Expresión Génica , Inmunohistoquímica , Inmunofenotipificación , Ganglios Linfáticos/patología , Ganglios Linfáticos/metabolismo , Linfoma no Hodgkin/patología , Linfoma no Hodgkin/metabolismo , Linfoma no Hodgkin/genética , Linfoma no Hodgkin/tratamiento farmacológico , Persona de Mediana Edad , Pronóstico , Proteína p53 Supresora de Tumor/inmunología , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/biosíntesis
7.
Artículo en Español | LILACS | ID: lil-263566

RESUMEN

La presente revisión bibliográfica de Linfoma No Hodgkin (LNH), un proceso cuya presentación es cada día más frecuente, y que corresponde en Chile al 7 por ciento del cáncer infantil. Se revisan aspectos de etiopatogenia, genéticos, inmunológicos e infecciosos que lo caracterizan, y que dependiendo de su variedad histológica determinan, sitios de ubicación, pronóstico y terapéutica. Se complementa con criterios actuales de estudio y tratamiento, insistiendo en las normas nacionales de nuestro país


Asunto(s)
Humanos , Niño , Linfoma no Hodgkin/diagnóstico , Biopsia , Linfoma no Hodgkin/etiología , Linfoma no Hodgkin/genética , Linfoma no Hodgkin/tratamiento farmacológico , Estadificación de Neoplasias , Pronóstico
8.
HB cient ; 4(3): 250-6, set.-dez. 1997.
Artículo en Portugués | LILACS | ID: lil-253981

RESUMEN

Linfomas não-Hodgkin são tumores sólidos do sistema imunológico curáveis por quimioterapia que constantemente têm incorporado novas categorias. Alguns aspectos da histomorfologia, da imunofenotipagem e da citogenética são fatores prognósticos da evolução clínica e da resposta ao tratamento. Pacientes considerados de alto risco na "Working Formulation" não respondem adequadamente aos esquemas terapêuticos atuais mas beneficiam-se com o uso de esquemas de baixa toxicidade. Faz-se necessário uma nova subclassificação deste grupo de pacientes para o planejamento e interpretação de novos ensaios terapêuticos. Linfomas são doenças complexas que necessitam pesquisas aprofundadas em nível clínico e molecular


Asunto(s)
Humanos , Linfoma no Hodgkin/genética , Linfoma no Hodgkin/patología , Pronóstico
9.
Journal of Korean Medical Science ; : 402-408, 1996.
Artículo en Inglés | WPRIM | ID: wpr-83326

RESUMEN

Paraffin-embedded tissue samples from 30 cases of non-Hodgkin's lymphoma(NHL) and 10 of reactive hyperplasia, were processed for interphase cytogenetic chromosomal study. We performed non-fluorescent in situ hybridization(NFISH) using the enzymatic method with digoxigenin-labeled DNA centromeric probes for chromosome 7,12,18 and X, and a painting probe for chromosome 18. Chromosomal aberrations were observed in 27(90%) out of 30 cases of NHL. The most commonly observed numerical aberration was extracopy of X chromosome. There were some characteristic aberrations corresponding to each grade and group of NHL by International Working Formulation: In low grade NHL(9 cases), a third were associated with extracopy of chromosome 12, and disomy X was frequently found in small lymphocytic lymphoma(75%). With intermediate grade(16 cases), tetraploidy(25%), translocation of chromosome 18(25%), and extracopy of chromosome 18(19%) were characteristically associated. These results suggest that interphase NFISH is an easily performable method in retrograde cytogenetic study of archival materials. Some specifically correlated chromosomal aberrations corresponding to the histopathologic grades and groups could provide us more valuable information for determining pathologic diagnosis and assessing the clinical outcome of NHL.


Asunto(s)
Humanos , Aberraciones Cromosómicas , Inmunofenotipificación , Hibridación in Situ , Interfase , Linfoma no Hodgkin/genética , Adhesión en Parafina , Seudolinfoma/genética
10.
Rev. Fed. méd. venez ; 1(1/2): 47-58, ene.-jun. 1993. tab
Artículo en Español | LILACS | ID: lil-141367

RESUMEN

En este trabajo, 34 pacientes con Linfoma (L) fueron estudiados prospectivamente, para determinar el valor diagnóstico de las alteraciones citogenéticas (AC) observadas en linfocitos en sangre periférica, médula ósea, ganglio linfático y líquido ascítico. La mayoría de los 11 pacientes con EH eran adolescentes o adultos jóvenes en estadio avanzado de la enfermedad. Los 23 pacientes con LNH eran mayores de 16 años, con una gran variedad de formas histológicas y se encontraban en estadio IV de la enfermedad. Más del 80 por ciento de los pacientes mostraron AC; las aneuploidías, translocaciones, delecciones y otros cambios estructurales cromosómicos; 3 pacientes con EH y 2 con LNH mostraron cromosoma Philadhelphia positivo, pareciendo tener este hallazgo un significado pronóstico sombrío en este último grupo. En los pacientes que fallecieron se observó en EH en forma simultánea, monosomía 22 y 7, y en LNH alteraciones estructurales y monosomía 22


Asunto(s)
Humanos , Citogenética , Enfermedad de Hodgkin/inducido químicamente , Enfermedad de Hodgkin/genética , Linfoma no Hodgkin/inducido químicamente , Linfoma no Hodgkin/genética
13.
Rev. invest. clín ; 44(2): 203-14, abr.-jun. 1992. ilus, tab
Artículo en Inglés | LILACS | ID: lil-118208

RESUMEN

En este artículo describimos la distribución anatómica, las características histológicas y moleculares de 32 casos de LNH. La estadificación clínica y clasificación histológica por grados se hizo de acuerdo a esquemas aceptados convencionalmente. Los arreglos detectados en genes que codifican para Ig o el RcT sirvieron para identificar la estirpe celular y el estadio de diferenciación de las células neoplásicas. El análisis de 26 muestras de suero reveló la existencia de anticuerpos contra epítopes de EBV; ocho de estos pacientes contenían secuencias virales integradas en el genoma del tumor. Nuestros estudios indican que el uso de diferentes métodos es fundamental para profundizar en el conocimiento de la historia natural de los LNH.


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Linfoma no Hodgkin/clasificación , Linfoma no Hodgkin/genética , Reordenamiento Génico de Linfocito T/genética , Genes myc/genética , Genes Relacionados con las Neoplasias/genética , Linfoma no Hodgkin/genética , México , Estadificación de Neoplasias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA